TY - JOUR
T1 - Cohort Profile
T2 - A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)
AU - Rossetti, Barbara
AU - Incardona, Francesca
AU - Di Teodoro, Giulia
AU - Mommo, Chiara
AU - Saladini, Francesco
AU - Kaiser, Rolf
AU - Sönnerborg, Anders
AU - Lengauer, Thomas
AU - Zazzi, Maurizio
AU - EuResist Network, INTEGRATE study group
AU - Seguin-Devaux, Carole
N1 - Acknowledgments: The EuResist study group: A. Abecasis: Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical-Universidade Nova de Lisboa, Lisbon, Portugal. M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia. C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg. F. Garcia, Hospital Universitario San Cecilio, Granada, Spain. F. Incardona, EuResist Network, Roma, Italy—IPRO, Roma, Italy. T. Lengauer, Max-Planck-Institut für Informatik, UniKlinik Köln, Germany. R. Kaiser, University of Cologne, Cologne, Germany. R. Paredes, Irsicaixa, Spain. B. Clotet, Irsicaixa, Spain. N. Pfeifer, Universität Tübingen, Germany. M. Rosen-Zvi, IBM Research, ISRAEL. M. Sayan, Kocaeli University, Medical Faculty, Turkey. A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden. A. M. Vandamme, REGA Institut KU Leuven, Belgium. M. Zazzi, University of Siena, Siena, Italy. Thanks to Maria Pia Fabiani for english language spell checked.
Funding: This research was funded by EuResist project (Grant n. IST-2004-027173, 6th EU Framework Programme); CHAIN-Collaborative HIV and Anti-HIV drug resistance Network (grant No Health-2007-223131, 7th EU Framework Programme); CARE-Common Action against HIV-TB HCV across the Regions of Europe (grant No 825673, Horizon 2020); EuCARE-European Cohorts of Patients and Schools to Advance Response to Epidemics (grant No 101046016, Horizon Europe); unrestricted research grants from the following pharmaceutical companies: Abbott, Janssen Tibotec, Gilead Sciences, Merck Sharp & Dohme, Pfizer, Theratechnologies, ViiV Healthcare
PY - 2023/4/23
Y1 - 2023/4/23
N2 - The EuResist cohort was established in 2006 with the purpose of developing a clinical decision-support tool predicting the most effective antiretroviral therapy (ART) for persons living with HIV (PLWH), based on their clinical and virological data. Further to continuous extensive data collection from several European countries, the EuResist cohort later widened its activity to the more general area of antiretroviral treatment resistance with a focus on virus evolution. The EuResist cohort has retrospectively enrolled PLWH, both treatment-naïve and treatment-experienced, under clinical follow-up from 1998, in nine national cohorts across Europe and beyond, and this article is an overview of its achievement. A clinically oriented treatment-response prediction system was released and made available online in 2008. Clinical and virological data have been collected from more than one hundred thousand PLWH, allowing for a number of studies on the response to treatment, selection and spread of resistance-associated mutations and the circulation of viral subtypes. Drawing from its interdisciplinary vocation, EuResist will continue to investigate clinical response to antiretroviral treatment against HIV and monitor the development and circulation of HIV drug resistance in clinical settings, along with the development of novel drugs and the introduction of new treatment strategies. The support of artificial intelligence in these activities is essential.
AB - The EuResist cohort was established in 2006 with the purpose of developing a clinical decision-support tool predicting the most effective antiretroviral therapy (ART) for persons living with HIV (PLWH), based on their clinical and virological data. Further to continuous extensive data collection from several European countries, the EuResist cohort later widened its activity to the more general area of antiretroviral treatment resistance with a focus on virus evolution. The EuResist cohort has retrospectively enrolled PLWH, both treatment-naïve and treatment-experienced, under clinical follow-up from 1998, in nine national cohorts across Europe and beyond, and this article is an overview of its achievement. A clinically oriented treatment-response prediction system was released and made available online in 2008. Clinical and virological data have been collected from more than one hundred thousand PLWH, allowing for a number of studies on the response to treatment, selection and spread of resistance-associated mutations and the circulation of viral subtypes. Drawing from its interdisciplinary vocation, EuResist will continue to investigate clinical response to antiretroviral treatment against HIV and monitor the development and circulation of HIV drug resistance in clinical settings, along with the development of novel drugs and the introduction of new treatment strategies. The support of artificial intelligence in these activities is essential.
KW - HIV
KW - HIV subtypes
KW - antiretroviral therapy
KW - drug resistance
KW - treatment-response prediction system
U2 - 10.3390/tropicalmed8050243
DO - 10.3390/tropicalmed8050243
M3 - Article
C2 - 37235291
SN - 2414-6366
VL - 8
JO - Tropical Medicine and Infectious Disease
JF - Tropical Medicine and Infectious Disease
IS - 5
M1 - 243
ER -